If only one of the trials is approved ( M2M or C2C) won’t doctors still be able to give Leronlimab to their patients who need it regardless? Who will be monitoring this since a diagnosis can be so subjective. A dr can just say his patient is somewhere in the middle and administer the drug, right? If so then a good result on one trial could open the door for all patients who need it. I don’t see how the FDA could monitor all these patients and doctors if one trial is successful. Thoughts?